Inotiv
CLOSE ×

Inotiv offers the highly regarded and well characterized Washington University Human in Mouse (WHIM) PDX models. This broad collection of breast cancer PDX cells encompass all of the major molecular subtypes and other notable attributes such as treatment resistance and sensitivity. Search by these criteria below.

Subject to availability

Order today

+1 800 793 7287

Online order  

Washington University Human in Mouse (WHIM) PDX models

WHIM Tumor Site Status
ER / PR / HER2
Details
WHIM2 Primary: Breast ER- / PR- / HER2-
TNBC
ESR1 genotype: WT
PIK3CA genotype2: WT
p53 genotype: S166S insertion
Whole genome sequenced: No
Exome sequenced: Unknown
RNAseq: Yes
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: p90RSK_pT359
PAM50 subtype originating tumor: Basal
PAM50 subtype early passage PDX: Basal
PAM50 subtype late passage PDX: Basal
Treatment prior to sample grafting: N/A
Treatment post sample grafting: Neoadj. DD doxorubicin, Cyclophosphomide, followed by Paclitaxel; Adj. chest wall radiation, Tamoxifen; Brain met;
Pathology specimen type: Surgery core primary
Pathology stage: 3A
Stage at sample grafting: 4
Pathology: Ductal, Lobular
Patient tumor grade: 3
Age at diagnosis: 44
Family history: None
Overall survival (months): 11
Patient race: African American
Propagated in NSG @ Inotiv: x
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 2
Notes: Same patient as WHIM 5
WHIM3 Primary: Breast ER- / PR- / HER2-
TNBC
ESR1 genotype: WT
PIK3CA genotype2: WT
p53 genotype: WT
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Src_pY527
PAM50 subtype originating tumor: HER2-E
PAM50 subtype early passage PDX:
PAM50 subtype late passage PDX:
Treatment prior to sample grafting: N/A
Treatment post sample grafting: Gemcitabine x1
Pathology specimen type: Unknown
Pathology stage: Unknown
Stage at sample grafting: Unknown
Pathology: Unknown
Patient tumor grade: Unknown
Age at diagnosis: Unknown
Family history: Unknown
Overall survival (months): Unknown
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 3
Notes:
WHIM4 Metastasis: Skin ER- / PR- / HER2-
TNBC
ESR1 genotype: WT
PIK3CA genotype2: WT
p53 genotype: R175H
Whole genome sequenced: Yes
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: p27_pT198
PAM50 subtype originating tumor: Basal
PAM50 subtype early passage PDX: Basal
PAM50 subtype late passage PDX: Basal
Treatment prior to sample grafting: Adj. Herceptin; Gem, Paclitaxel, Herceptin; Capecitabine
Treatment post sample grafting: Bevacizumab, Docetaxel chest wall radiation, Tamoxifen; Brain met;
Pathology specimen type: Core abdominal wall recurrence
Pathology stage: PathCR
Stage at sample grafting: 4
Pathology: Ductal
Patient tumor grade: 3
Age at diagnosis: 49
Family history: None
Overall survival (months): 37
Patient race: African American
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 4
Notes:
WHIM5
in stock
Metastasis: Brain ER- / PR- / HER2-
TNBC
ESR1 genotype: WT
PIK3CA genotype2: WT
p53 genotype: S166S insertion
Whole genome sequenced: Yes
Exome sequenced: No
RNAseq: Yes
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: p90RSK_pT359
PAM50 subtype originating tumor: Basal
PAM50 subtype early passage PDX: Basal
PAM50 subtype late passage PDX: Basal
Treatment prior to sample grafting: Neoadj. DD doxorubicin, Cyclophosphomide, followed by Paclitaxel;
Adj. chest wall radiation, Tamoxifen; Brain met
Treatment post sample grafting: N/A
Pathology specimen type: Surgical specimen, brain – posterior fossa; surgery core primary
Pathology stage: 3A
Stage at sample grafting: 4
Pathology: Ductal, Lobular
Patient tumor grade: 3
Age at diagnosis: 44
Family history: Unknown
Overall survival (months): 11
Patient race: African American
Propagated in NSG @ Inotiv: x
Completed efficacy study: x
Estradiol response: Unknown
WHIM number: 5
Notes: Same patient as WHIM 2
WHIM6 Primary: Breast ER- / PR- / HER2-
TNBC
ESR1 genotype: WT
PIK3CA genotype2: WT
p53 genotype: WT
Whole genome sequenced: Yes
Exome sequenced: No
RNAseq: Yes
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: PRAS40_pT246
PAM50 subtype originating tumor: Basal
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: N/A
Treatment post sample grafting: neo 5FU, epirubicin, cyclophosphamide; Left Breast Excision; chest wall radiation; Nab-Paclitaxel; Capecitabine; 5FU, Epirubicin, Cyclophosphamide; Doxorubicin; Gemcitabine; Navelbine
Pathology specimen type: Unknown
Pathology stage: Unknown
Stage at sample grafting: Unknown
Pathology: Unknown
Patient tumor grade: Unknown
Age at diagnosis: Unknown
Family history: Unknown
Overall survival (months): Unknown
Patient race: African American
Propagated in NSG @ Inotiv: x
Completed efficacy study: x
Estradiol response: Unknown
WHIM number: 6
Notes:
WHIM8
in stock
Metastasis: Skin ER- / PR- / HER2+ ESR1 genotype: WT
PIK3CA genotype2: WT
p53 genotype: Y234H
Whole genome sequenced: Yes
Exome sequenced: No
RNAseq: Yes
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Shc_pY317
PAM50 subtype originating tumor: Basal
PAM50 subtype early passage PDX: HER2-E
PAM50 subtype late passage PDX: HER2-E
Treatment prior to sample grafting: Adj. Docetaxol, Doxorubicin, Cylcophosphamide; Tamoxifen;
Local recurrence Chest Wall; Anastrozole; Liver met; Carboplatin, Paclitaxel, and Herceptin; Navelbine and Herceptin; Gemcitabine and Herceptin; Herceptin and Capecitabine; 5FU, Epirubicin, Cyclophosphomide; radiation; Nab-Paclitaxel and Herceptin; Capecitabine and Lapatinib
Treatment post sample grafting: CCI-779; Docetaxol and Bevacizumab
Pathology specimen type: Punch Chestwall
Pathology stage: 2B
Stage at sample grafting: 4
Pathology: Ductal
Patient tumor grade: 3
Age at diagnosis: 37
Family history: Maternal Aunt
Overall survival (months): 113
Patient race: Caucasian
Propagated in NSG @ Inotiv: x
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 8
Notes:
WHIM9 Metastasis: Skin ER+ / PR+ / HER2- ESR1 genotype: WT
PIK3CA genotype2: H1047R
p53 genotype: WT
Whole genome sequenced: Yes
Exome sequenced: No
RNAseq: Yes
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Akt_pS474
PAM50 subtype originating tumor: Luminal A
PAM50 subtype early passage PDX: Luminal B
PAM50 subtype late passage PDX: Luminal B
Treatment prior to sample grafting: Adj. radiation; Letrozole and Zoladex; Letrozole
Treatment post sample grafting: Fulvestrant +/- Lapatinib on protocol; Aromasin; Capecitabine;
Tamoxifen; Estradiol; Doxorubicin, Doxorubicin + CCI-779; Megace; Nab-Paclitaxel
Pathology specimen type: Punch Chestwall
Pathology stage: N/A
Stage at sample grafting: 4
Pathology: Ductal
Patient tumor grade: 3
Age at diagnosis: 47
Family history: Unknown
Overall survival (months): 129
Patient race: African American
Propagated in NSG @ Inotiv: x
Completed efficacy study: No
Estradiol response: Independent
WHIM number: 9
Notes:
WHIM10 Primary: Breast ER- / PR- / HER2-
TNBC
ESR1 genotype: WT
PIK3CA genotype2: WT
p53 genotype: Y220C
Whole genome sequenced: No
Exome sequenced: Unknown
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: N/A
PAM50 subtype originating tumor: Basal
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Unknown
Treatment post sample grafting: Unkown
Pathology specimen type: Unknown
Pathology stage: Unknown
Stage at sample grafting: Unknown
Pathology: Unknown
Patient tumor grade: Unknown
Age at diagnosis: Unknown
Family history: Unknown
Overall survival (months): Unknown
Patient race: Unknown
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 10
Notes:
WHIM11
in stock
Primary: Breast ER+ / PR- / HER2- ESR1 genotype: WT
PIK3CA genotype2: WT
p53 genotype: D148X insertion
Whole genome sequenced: Yes
Exome sequenced: No
RNAseq: Yes
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: p70S6K_pT389
PAM50 subtype originating tumor: HER2-E
PAM50 subtype early passage PDX: Luminal B
PAM50 subtype late passage PDX: Her2-E
Treatment prior to sample grafting: Letrozole, radiation
Treatment post sample grafting: Fulvestrant +/- Lapatinib on study; Exemestane; mastectomy with
LN dissection, chest wall radiation; radiation to spine; brain met; whole brain radiation; Paclitaxel, Bevacizumab; Capecitabine; Quadramet given for pain; Anastrozole
Pathology specimen type: Surgery core primary
Pathology stage: 4
Stage at sample grafting: 4
Pathology: Ductal
Patient tumor grade: 3
Age at diagnosis: 40
Family history: Paternal Grandmother
Overall survival (months): 37
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Independent
WHIM number: 11
Notes:
WHIM12 Primary: Breast ER- / PR- / HER2-
TNBC
ESR1 genotype: WT
PIK3CA genotype2: WT
p53 genotype: R248Q
Whole genome sequenced: Yes
Exome sequenced: No
RNAseq: Yes
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: AKT_pT308
PAM50 subtype originating tumor: Claudin Low
PAM50 subtype early passage PDX: Claudin Low
PAM50 subtype late passage PDX: Claudin Low
Treatment prior to sample grafting: N/A
Treatment post sample grafting: Adj. 5FU, Epirubicin, Cyclophosphamide, followed by Docetaxel;
chest wall radiation; relapse; Paclitaxel, Bevacizumab; Bevacizumab held sec to low EF; Paclitaxel, Carboplatin
Pathology specimen type: Surgery - Primary
Pathology stage: 2B
Stage at sample grafting: 2B
Pathology: Metaplastic
Patient tumor grade: 3
Age at diagnosis: Unknown
Family history: Unknown
Overall survival (months): 12
Patient race: Caucasian
Propagated in NSG @ Inotiv: x
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 12
Notes:
WHIM13 Metastasis: Skin ER- / PR- / HER2-
TNBC
ESR1 genotype: WT
PIK3CA genotype2: WT
p53 genotype: C238Y
Whole genome sequenced: Yes
Exome sequenced: No
RNAseq: Yes
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Src_pY527
PAM50 subtype originating tumor: Basal
PAM50 subtype early passage PDX: Basal
PAM50 subtype late passage PDX: Basal
Treatment prior to sample grafting: Neoadj. Doxorubicin, Cyclophosphamide + Docetaxol; adjuvant radiation- whole breast andregional node; ipsilateral breast recurrence; bilateral mastectomies; no treatment; chest wall recurrence; chest wall radiation; Nab-Paclitaxel, Bevacizumab x4 cycles; chemo break
Treatment post sample grafting: Radiation to chest wall and regional nodes; liver and lung met; Capecitabine; Doxorubicin; Nab-Paclitaxel, Bevacizumab, Carboplatin, Gemcitabine
Pathology specimen type: Punch -skin recurrence, surgery – chest wall skin recurrence
Pathology stage: 2A
Stage at sample grafting: 4
Pathology: Ductal, Lobular
Patient tumor grade: 2
Age at diagnosis: 42
Family history: Maternal Aunt
Overall survival (months): 44
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 13
Notes:
WHIM14
in stock
Metastasis: Skin ER- / PR- / HER2-
TNBC
ESR1 genotype: WT
PIK3CA genotype2: WT
p53 genotype: I195T
Whole genome sequenced: Yes
Exome sequenced:
RNAseq: Yes
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: N/A
PAM50 subtype originating tumor: Basal
PAM50 subtype early passage PDX:
PAM50 subtype late passage PDX:
Treatment prior to sample grafting:
Treatment post sample grafting:
Pathology specimen type:
Pathology stage:
Stage at sample grafting:
Pathology:
Patient tumor grade:
Age at diagnosis:
Family history:
Overall survival (months):
Patient race: Caucasian
Propagated in NSG @ Inotiv: x
Completed efficacy study:
Estradiol response:
WHIM number: 14
Notes:
WHIM16
in stock
Metastasis: Skin ER+ / PR+ / HER2- ESR1 genotype: AMP
PIK3CA genotype2: H1047R
p53 genotype: R248W
Whole genome sequenced: Yes
Exome sequenced: No
RNAseq: Yes
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: 4E-BP1_pT37
PAM50 subtype originating tumor: Luminal B
PAM50 subtype early passage PDX: Luminal A
PAM50 subtype late passage PDX: Luminal B
Treatment prior to sample grafting: 8 cycles of adj. DD doxorubicin, Cylcophosphomide followed by
Gemcitabine; radiation to right breast and axilla; Exemestane; recurrence to bone; Fulvestrant; palliative radiation to thoracic spine; Capecitabine; Estradiol
Treatment post sample grafting: Paclitaxel, Bevacizumab
Pathology specimen type: Punch -Skin recurrence
Pathology stage: 3A
Stage at sample grafting: 4
Pathology: Ductal
Patient tumor grade: 3
Age at diagnosis: 64
Family history: Mother
Maternal Aunt (x2)
Overall survival (months): 56
Patient race: Caucasian
Propagated in NSG @ Inotiv: x
Completed efficacy study: x
Estradiol response: Responsive
WHIM number: 16
Notes:
WHIM18
in stock
Metastasis: Skin ER+ / PR+ / HER2- ESR1 genotype: ESR1 YAP1
PIK3CA genotype2: E545K
p53 genotype: WT
Whole genome sequenced: Yes
Exome sequenced: Unknown
RNAseq: Yes
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: ER-alpha_pS118
PAM50 subtype originating tumor: Luminal A
PAM50 subtype early passage PDX: Luminal B
PAM50 subtype late passage PDX: Luminal B
Treatment prior to sample grafting: Letrozole; Exemestane; Fulvestrant
Treatment post sample grafting: Capecitabine; Paclitaxel, Bevacizumab; Tamoxifen; Radiation to the calvarium completed; Doxil
Pathology specimen type: Punch - Primary
Pathology stage: 4
Stage at sample grafting: 4
Pathology: Ductal
Patient tumor grade: 2
Age at diagnosis: 57
Family history: None
Overall survival (months): 31
Patient race: African American
Propagated in NSG @ Inotiv: x
Completed efficacy study: x
Estradiol response: Independent
WHIM number: 18
Notes:
WHIM20
in stock
Metastasis: Skin ER+ / PR+ / HER2- ESR1 genotype: Y537S
PIK3CA genotype2: E542K
p53 genotype: C182X
Whole genome sequenced: Yes
Exome sequenced: No
RNAseq: Yes
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: PDK1_pS241
PAM50 subtype originating tumor: Luminal B
PAM50 subtype early passage PDX: Luminal A
PAM50 subtype late passage PDX: Luminal B
Treatment prior to sample grafting: Adj. Docetaxol, Carboplatin Alternating with Epirubicin,
Cyclophosphomide x4 cycles; radiation; Tamoxifen; first recurrence; Docetaxol, Carboplatin; Letrozole; Fulvestrant; Vinorelbine, Capecitabine; Capecitabine, Fulvestrant; Capecitabine; Paclitaxel, Bevacizumab, bev held multiple times; Paclitaxel
Treatment post sample grafting: IMC-A12, Temsirolimus on study; Exemestane; Estradiol; doxorubicin liposomal; methotrexate, cyclophosphomide; radiation to right face and neck; Eribulin
Pathology specimen type: Punch - Skin right clavicle
Pathology stage: 3A
Stage at sample grafting: 4
Pathology: Ductal, Lobular
Patient tumor grade: 1
Age at diagnosis: 36
Family history: Mother
Overall survival (months): 37
Patient race: Caucasian
Propagated in NSG @ Inotiv: x
Completed efficacy study: x
Estradiol response: Independent
WHIM number: 20
Notes: Same Patient as WHIM23
WHIM21 Primary: Breast ER- / PR- / HER2-
TNBC
ESR1 genotype: WT
PIK3CA genotype2: WT
p53 genotype: P151H
Whole genome sequenced: Yes
Exome sequenced:
RNAseq: Yes
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Chk1_pS345
PAM50 subtype originating tumor: Basal
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Neoadj. Doxorubicin, Cyclophosphamide followed by Paclitaxel
Treatment post sample grafting: Recurrence; radiation to chest wall and whole brain; Capecitabine,
Ixabepilone
Pathology specimen type: Unknown
Pathology stage: Unknown
Stage at sample grafting: Unknown
Pathology: Unknown
Patient tumor grade: Unknown
Age at diagnosis: Unknown
Family history: Unknown
Overall survival (months): Unknown
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 21
Notes:
WHIM22 Metastasis: Skin ER- / PR- / HER2+ ESR1 genotype: WT
PIK3CA genotype2: WT
p53 genotype: C275F
Whole genome sequenced: No
Exome sequenced: Unknown
RNAseq: Yes
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: EGFR_pY1068
PAM50 subtype originating tumor: Basal
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Adj. Doxorubicin, Cyclophosphamide, breast radiation, Paclitaxel,
Herceptin, Herceptin 6/11/2007, Tamoxifen, local recurrance; Paclitaxel, Carboplatin, Herceptin; mastectomy; chest wall recurrence; Anastrozole
Treatment post sample grafting: Abraxane, Bevacizumab, Anastrozole
Pathology specimen type: Unknown
Pathology stage: Unknown
Stage at sample grafting: Unknown
Pathology: Unknown
Patient tumor grade: Unknown
Age at diagnosis: Unknown
Family history: Unknown
Overall survival (months): Unknown
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 22
Notes:
WHIM23 Metastasis: Node ER+ / PR+ / HER2- ESR1 genotype: Y537S
PIK3CA genotype2: E542K
p53 genotype: C182X
Whole genome sequenced: No
Exome sequenced: Unknown
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Rb_pS807_S811
PAM50 subtype originating tumor: Luminal B
PAM50 subtype early passage PDX: Luminal A
PAM50 subtype late passage PDX: Luminal B
Treatment prior to sample grafting: Adj. Docetaxol, Carboplatin Alternating with Epirubicin,
Cyclophosphomide x4 cycles; radiation; Tamoxifen; first recurrence; Docetaxol, Carboplatin; Letrozole; Fulvestrant; Vinorelbine, Capecitabine; Capecitabine, Fulvestrant; Capecitabine; Paclitaxel,
Bevacizumab, bev held multiple times; Paclitaxel; IMC-A12, Temsirolimus on study; Exemestane
Treatment post sample grafting: Estradiol; doxorubicin liposomal; methotrexate, cyclophosphomide;
radiation to right face and neck; Eribulin
Pathology specimen type: Punch - Skin right clavicle
Pathology stage: 3A
Stage at sample grafting: 4
Pathology: Ductal, Lobular
Patient tumor grade: 1
Age at diagnosis: 36
Family history: Mother
Overall survival (months): 97
Patient race: Caucasian
Propagated in NSG @ Inotiv: x
Completed efficacy study: No
Estradiol response: Independent
WHIM number: 23
Notes: Same Patient as WHIM20
WHIM24 Primary: Breast ER+ / PR+ / HER2- ESR1 genotype: E380Q
PIK3CA genotype2: H1047K
p53 genotype: WT
Whole genome sequenced: Yes
Exome sequenced: Unknown
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: ER-alpha_pS118
PAM50 subtype originating tumor: Luminal B
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Adj. Adriamycin, Cyclophosphomide bilateral breast radiation;
Tamoxifen; recurrence, Docetaxol, Exemestane, Capecitabine, Doxorubicin liposomal x1 dose d/c due to high blood sugars; Fulvestrant, Estradiol 6mg; Gemcitabine, Navelbine; Docetaxol; Ixabepilone; possible tamoxifen--patient denies this; Nab-Paclitaxel x1 dose; Fulvestrant; Capecitabine; Carboplatin x1 dose
Treatment post sample grafting: Estradiol 6mg, Methotrexate, Cyclophosphomide; Paclitaxel,
Bevacizumab; Tamoxifen; Fulvestrant; Tamoxifen and Afinitor
Pathology specimen type: Unknown
Pathology stage: Unknown
Stage at sample grafting: Unknown
Pathology: Unknown
Patient tumor grade: Unknown
Age at diagnosis: Unknown
Family history: Unknown
Overall survival (months): Unknown
Patient race: Unknown
Propagated in NSG @ Inotiv:No
Completed efficacy study: No
Estradiol response: Dependent
WHIM number: 24
Notes:
WHIM25 Metastasis: Skin ER- / PR- / HER2-
TNBC
ESR1 genotype: WT
PIK3CA genotype2: WT
p53 genotype: R273H
Whole genome sequenced: Yes
Exome sequenced:
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: MAPK_pT202_Y204
PAM50 subtype originating tumor: Basal
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Paclitaxel with Bevacizumab followed by AC with Bevaxizumab
Treatment post sample grafting: UCN1 and Irinotecan
Pathology specimen type: Unknown
Pathology stage: Unknown
Stage at sample grafting: Unknown
Pathology: Unknown
Patient tumor grade: Unknown
Age at diagnosis: Unknown
Family history: Unknown
Overall survival (months): Unknown
Patient race: African American
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 25
Notes: Same patient as WHIM 5
WHIM26 Metastasis: Node ER+ / PR+ / HER2- ESR1 genotype: WT
PIK3CA genotype2: WT
p53 genotype: WT
Whole genome sequenced: Yes
Exome sequenced:
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: mTOR_pS2448
PAM50 subtype originating tumor: Luminal B
PAM50 subtype early passage PDX: Luminal A
PAM50 subtype late passage PDX: Luminal B
Treatment prior to sample grafting: Premarin; Anastrozole; Estradiol; Arimidex; Estradiol, Tamoxifen
Treatment post sample grafting: Xeloda, Radiation to chest wall and right supraclavicular fossa
Pathology specimen type: Surgical – lymph node, right supraclavicular, biopsy
Pathology stage: 2A
Stage at sample grafting: 4
Pathology: Metastatic micropapillary carcinoma
Patient tumor grade: Unknown
Age at diagnosis: 59
Family history: None
Overall survival (months): 283
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 26
Notes:
WHIM27 Metastasis: Liver ER+ / PR+ / HER2- ESR1 genotype: Y537N
PIK3CA genotype2: WT
p53 genotype: Del 1022_1033
Whole genome sequenced: No
Exome sequenced: Yes
RNAseq: Yes
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Luminal B
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Luminal B
Treatment prior to sample grafting: R modified radical mastectomy; CMFx 2 (did not tolerate); FACx4
XRT chest wall; Tamoxifenx 6 months (discontinuation unknown); Recurrence in mediastinal LN and bone; Letrozole, Zometa; bone progression, R shoulder sub-q met, R scalp met; Estradiol 6 mg for 4 weeks until porogressionm; Falsodex (d/c due to progression); Xeloda (d/c due to progression); brian met;
XRT 15 treatments to brian, Tamoxifen; Avastin, Taxotere; Avastin; Herceptin (no response); CMF; Avastin, Taxol; Methotrexate, Cyclephopsphamide (one dose); Carboplatin and Gemcitabine; Ixabepilone; liver met
Treatment post sample grafting: Falsodex;
Pathology specimen type: Liver Needle Biopsy
Pathology stage: T2N1M0 (at diagnosis)
Stage at sample grafting: 4
Pathology: Ductal, infiltrating
Patient tumor grade: Unknown
Age at diagnosis: Unknown
Family history: Unknown
Overall survival (months): 186
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 27
Notes:
WHIM29 Primary: Breast ER- / PR- / HER2-
TNBC
ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: N/A
Treatment post sample grafting: N/A
Pathology specimen type: L breast biopsy during port placement
Pathology stage: T4N3M1 (at diagnosis)
Stage at sample grafting: 4
Pathology: Ductal, infiltrating
Patient tumor grade: Not given
Age at diagnosis: Unknown (post-menopausal)
Family history: Unknown
Overall survival (months): Unknown (<10 months)
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 29
Notes:
WHIM30 Primary: Breast ER- / PR- / HER2-
TNBC
ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: N/A
Treatment post sample grafting: Neo. Adj. Paclitaxel (x4 cycles) followed by Adriamycin/Cytoxon (x4 cycles) on trial; left and right breast mastectomy and left axillary node dissection (neg. for residual disease); radiation to L chest wall and regional lymphatics; bilateral ooporectomy; L breast implant removal
Pathology specimen type: L Breast core biopsy
Pathology stage: T3N2M0
Stage at sample grafting: T3N2M0
Pathology: Ductal, invasive
Patient tumor grade: 3
Age at diagnosis: 35 (pre-menapausal)
Family history: Unknown
Overall survival (months): Still alive at reporting No evidence of recurrance (46)
Patient race: Asian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 30
Notes: Patient BRCA2 mutation+
WHIM31 Metastasis: Adomen
(sub-q)
ER- / PR- / HER2-
TNBC
ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: s/p lumpectomy and radiation, adjuvant ACx4, Docetaxel x4;
Recurrent L breast cancer; mastectomy; Adj. Taxol, Carboplatin; Hysterectomy and oophorectomy; Arimidex; Reccurence L breast; Tamoxifen; new nodule; Falsodex; chest soft tissue mass and lung mets; Xeloda/Avastin; Avastin stopped; Xeloda dose reduction; chest wall mass progression; Navelbine/Gemcitabine; brain mets, lung met; CMF; brain radiation; Cytotoxan; chest mass progression; Gemcitabine, Carboplatin; Eribulin; Enlargin RUL
mass; Chest radiation ; Sub-q nodules in R lower quadrant of abdomen
Treatment post sample grafting: Doxorubicin
Pathology specimen type: Biopsy
Pathology stage: 3A (at diagnosis)
Stage at sample grafting: 4
Pathology: Not given
Patient tumor grade: 3 (at diagnosis)
Age at diagnosis: Unknown (post-menopausal)
Family history: Unknown
Overall survival (months): 115
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 31
Notes: Patient BRCA-1 mutation +
WHIM32 Recurrance: L breast
(R breast primary)
ER+ / PR- / HER2- ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: R modified mastectomy with LND and prophylactic L simple
mastectomy; Adj. ACx4 cycles; Taxoterex4 cycles; liver mets; adj. radiation; Adj. Tamoxifen; bone mets; Falsodex, Zometa; (Abraxane, Avastin, Zometa) x 6 cycles; Avastin, Falsodex, Zometa; liver mets, reactivation of bone mets;
(Avastin, Abraxane, Zometa)X 3 cyles (therpay held 8 dyas duing episode of collitis); Xeloda; Avastin, Zometa; Xelodda; Adenxal mass; Lupron, Femara; Carboplatin, Gemcitabine
Treatment post sample grafting: Several treatmetn breaks, during treatmetn break had trial of
Aromasin followed by single agent Carboplatin; Erubulin; Everlimus, Tamoxifen; Affinitor, Tamoxifen
Pathology specimen type: L Breast Skin Biobsy
Pathology stage: T2N2M0 (at diagnosis)
Stage at sample grafting: 4
Pathology: Ductal, invasive
Patient tumor grade: 2/3
Age at diagnosis: Unknown (post-menapausal)
Family history: Unknown
Overall survival (months): 35
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 32
Notes: Patient BRCA 1&2 testing negative
WHIM33 Breast: Primary ER- / PR- / HER2-
TNBC
ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Mets to brain, lung, and liver; Whole brain radiation
Treatment post sample grafting: Paclitaxel;
Pathology specimen type: Repeat L breast core biopsy
Pathology stage: Not given
Stage at sample grafting: 4
Pathology: Ductal, invasive
Patient tumor grade: 3
Age at diagnosis: Unknown (post-menopausal)
Family history: Unknown
Overall survival (months): 8
Patient race: African American
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 33
Notes:
WHIM34 Metastasis: R thigh ER- / PR- / HER2-
TNBC
ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Lumpecomy; S/p whole breast radiation; mets to skin, L breast,
mediastinum, liver, sacrum
Treatment post sample grafting: Brain met; whole brain radiation; Abraxane; unknown
Pathology specimen type: R tihgh biopsy
Pathology stage: TxN0M0 (suspected T2)
Stage at sample grafting: 4
Pathology: Intracystic papillary Infiltrating
Patient tumor grade: Not given
Age at diagnosis: Unknown (pre-menopusal)
Family history: Unknown
Overall survival (months): Still Alive at Reporting (52)
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 34
Notes:
WHIM35
in stock
Primary: Breast ER+ / PR+ / HER2+ ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: Unknown
Exome sequenced: Unknown
RNAseq: Unknown
Gene expression (microarray data) available: Unknown
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: N/A
Treatment post sample grafting: Neo adj. weekly taxol plus herceptin x12 (tumor shrinkage);
FEC, Herceptin Q 3 week x 4 cycles (SD); Bilateral modified radical mastectomy; Adj. Herceptin, tamoxifen (tam. Stopped for chemo), XTR of chest wall and draining lymph nodes; local chest wall reccurence and lymph (while on Herceptin); XRT and hyperthermia to left chest wall and draining lymphatics: Taxotere, Carbo and Herceptin Q3 week x 4; Herceptin; new arm mass; XRT - 15 treatments to left mid arm and new arm lesion; skin lesions; Kadcyla Q3 week; Herceptin, Perjeta, Paclitaxel
Pathology specimen type: Left breast core biopsy
Pathology stage: T3N3
Stage at sample grafting: T3N3
Pathology: Infiltrating Ductal Carcinoma
Patient tumor grade: 2
Age at diagnosis: 45 (Pre-menopausal)
Family history: Unknown
Overall survival (months): 42
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 35
Notes: Bilateral primary tumors, tumor in right breast was Her2-, left Her2+
WHIM36 Metastasis: Skin ER- / PR- / HER2-
TNBC
ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: Unknown
Exome sequenced: Unknown
RNAseq: Unknown
Gene expression (microarray data) available: Unknown
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Neoadj. AC x4, followed by lumpectomy/R axillary LN; Adj. taxol x12,
followed by radiation; Skin met, right breast; modified radical mastectomy; Local regional inflammatory disease recurrence; Iniparib (x16), Carboplatin (x7), Gemcitabine on trial, terminated due to toxicity; Chest wall recurrence
Treatment post sample grafting: Xeloda, addition of Cyclophosphamide, Local radiation
Pathology specimen type: Chest wall punch biopsy
Pathology stage: pT1cpN3a
Stage at sample grafting: 4
Pathology: Ductal, Invasive
Patient tumor grade: 3
Age at diagnosis: Unknown (pre-menopausal)
Family history: Unknown
Overall survival (months): 42
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 36
Notes:
WHIM37 Metastasi: Left femoral head ER+ / PR+ / HER2- ESR1 genotype: D538G
PIK3CA genotype2: WT
p53 genotype: I195T, R213R
Whole genome sequenced: No
Exome sequenced: Yes
RNAseq: Yes
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Luminal B
PAM50 subtype late passage PDX: Luminal B
Treatment prior to sample grafting: Neo adj. AC, Taxotere; R modified radical mastectomy; Adj. Arimidex; Bone Metastasis; Radiation; Fulvestrant, Zometa; Lung metastasis; Xeloda, Zometa; Abraxane, Zometa; Left auxillary lymphnode metatasis
Treatment post sample grafting: Estradiol, Zometa; Discontinuation of Estradiol, addiotn of Erbulin;
Liver metastasis; Erbulin discontinued, Tamoxifen initiated; Fulvestrant, Zometa
Pathology specimen type: L femoral head excision
Pathology stage: Unknown
Stage at sample grafting: 4
Pathology: Ductal
Patient tumor grade: Not given
Age at diagnosis: 58
Family history: Unknown
Overall survival (months): 75
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 37
Notes:
WHIM39 Metastasis: Skin ER- / PR- / HER2-
TNBC
ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: No
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: R mastectomy and sentinel LN biopsy w/ immediate reconstruction; Adj. Taxotere, cyclophosphamide; Adj. Arimidex; Mets to skin, LN, bone/spine
Treatment post sample grafting: Radiation to thoracic spine x10 cycles; Falsodex; Doxil
Pathology specimen type: Skin punch Biopsy
Pathology stage: T2N0M0 (at diagnosis)
Stage at sample grafting: 4
Pathology: Ductal, Invasive
Patient tumor grade: 3
Age at diagnosis: Unknown (post-menopausal)
Family history: Unknown
Overall survival (months): 25
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 39
Notes: Path report did not discover evidency of malignancy in skin punch biopsy
WHIM40 Metastasis: Left
auxillary lymph
node
ER+ / PR+ / HER2- ESR1 genotype: WT
PIK3CA genotype2: WT
p53 genotype: L265Q, D281G, L323L
Whole genome sequenced: No
Exome sequenced: Yes
RNAseq: Yes
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Luminal B
PAM50 subtype early passage PDX: Luminal B
PAM50 subtype late passage PDX: Luminal B
Treatment prior to sample grafting: Unknown
Treatment post sample grafting: Unknown
Pathology specimen type: Unknown
Pathology stage: Unknown
Stage at sample grafting: 4
Pathology: Ductal
Patient tumor grade: Not given
Age at diagnosis: Unknown
Family history: Unknown
Overall survival (months): Still Alive at Reporting
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 40
Notes:
WHIM41 Metastasis: Skin Chest wall ER- (?) / PR- (?) / HER2- (?)
TNBC
ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Adj. AC followed by Taxol; Chest wall radiation; Chest wall and L
auxillary LN reccurence; Abraxane, Avastin x3 then progressed; Chest wall reccurence; Gemzar, Xeloda x6 then progressed; Carboplatin, Taxotere; right chest wall reccurence
Treatment post sample grafting: Erlubin (?), F/U
Pathology specimen type: R chest wall punch biopsy
Pathology stage: Unknown
Stage at sample grafting: 4
Pathology: Ductal (primary)
Patient tumor grade: Not given
Age at diagnosis: Unknown (premenopausal)
Family history: Unknown
Overall survival (months): 41
Patient race: African American
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 41
Notes: ER/PR/HER2 status not reported for sample grafted. Previously TNBC. Patient sample Sequenced, neg for EGFR, MLL, ALK rearrangements
WHIM43
in stock
Metastasis: Right Rib ER+ / PR+ / HER2+ ESR1 genotype: D538G
PIK3CA genotype2: WT
p53 genotype: WT
Whole genome sequenced: No
Exome sequenced: Yes
RNAseq: Yes
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Luminal B
PAM50 subtype early passage PDX: Luminal B
PAM50 subtype late passage PDX: Luminal B
Treatment prior to sample grafting: Adj. Doxorubicin and Cyclophosphamide x4 followed by Paclitaxel x4 followed by radiation; Tamoxifen for ~3 years; first reoccurrence; Letrozole; Arimidex; Aromasin; Taxol and Avastin; Faslodex/Zometa; progression of pulmonary pleural disease, liver lesions, and new spinal metastases; Carboplatin/Gemcitabine with Zometa followed by Eribulin
Treatment post sample grafting: N/A
Pathology specimen type: Right rib needle biopsy
Pathology stage: Unknown
Stage at sample grafting: 4
Pathology: Ductal
Patient tumor grade: 3
Age at diagnosis: Unknown
Family history: Unknown
Overall survival (months): 81
Patient race: Caucasian
Propagated in NSG @ Inotiv: x
Completed efficacy study: x
Estradiol response: Inhibited
WHIM number: 43
Notes:
WHIM51 Recurrence/Metastasis:
Chest wall
ER+ / PR+ / HER2+ ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: L mastectomy; Adj. CMF; Radiation; Tamoxifen; Tamoxifen discontinued due to headaches; Thyroid gland metastasis; Tamoxifen and Zoladex; Tamoxifgen d/c due to progression; Bone met; Zoladex, herceptin, letrozole; discontinued due to
bone met progression; Exemestane and Lupron; Herceptin added; Exemestane d/c due to plural effusion; Herceptin, Lupron; Fulvestrant started; Discontinued due to progression; lung met; Xeloda, discontinued due to progression; Exemestane, goserelin, addition of metronomic chemotherpay w/ cyclophosphamide, methotrexate;
Treatment post sample grafting: Gemcitabine, carboplatin; d/c due to progression in omentum and peritoneum; Paclitaxel d/c due to progression; Armoasin, Everlimus, d/c due to acute renal failure; Anostrozole; brain met; whole brain radiation; Anastrozole d/c; Lapatinib
Pathology specimen type: Skin punch Biopsy
Pathology stage: pT2N0 (at diagnosis)
Stage at sample grafting: 4
Pathology: Not given
Patient tumor grade: Not given
Age at diagnosis: 36
Family history: Unknown
Overall survival (months): 51
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 51
Notes: Patient BRCA negative
WHIM53 Metastasis/Reccurence: Left Breast Skin ER- / PR- / HER2-
TNBC
ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Refused adj. chemo and radiation; skin thickening w/ mulitple hypermetabolic foci in lung and breast and LN mets; Taxotere
Treatment post sample grafting: Brain met; whole brain radiation
Pathology specimen type: Left breast skin punch biopsy
Pathology stage: Unknown
Stage at sample grafting: Unknown
Pathology: Invasive ductal
Patient tumor grade: 3
Age at diagnosis: Unknown (post-menopausal)
Family history: Unknown
Overall survival (months): 19
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 53
Notes:
WHIM55 Recurrence/Metastasis:
Chest wall
ER- / PR- / HER2-
TNBC
ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting:Lumpectomy and sentinel LN dissection; axillary LN dissection; Adj. Adriamycin, Cytoxan followed by Taxol; R chest wall and LN radition; Bone met and chest wall recurrence; Capecitabine, discontinued due to increased nodularity; radiation
Treatment post sample grafting: Paclitaxel, discontinued due to disease progression; unknown
Pathology specimen type: Skin punch Biopsy
Pathology stage: Unknown
Stage at sample grafting: 4
Pathology: Not given
Patient tumor grade: Not given
Age at diagnosis: 45
Family history: Unknown
Overall survival (months): 34
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 55
Notes: Patient BRCA1,2 negative
WHIM56 Primary: Breast ER- / PR- / HER2+ ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: N/A
Treatment post sample grafting: THP; therapies stopped due to heart failure; unknown
Pathology specimen type: R core biopsy during port placement
Pathology stage: Not given
Stage at sample grafting: 4
Pathology: Ductal, invasive
Patient tumor grade: 3
Age at diagnosis: 29 (pre-menopausal)
Family history: Unknown
Overall survival (months): Still alive at reporting (32)
Patient race: African American
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 56
Notes:
WHIM58 Metastasis: Sternum ER+ / PR+ / HER2- ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Neo adj. Anastrazole,; FEC-T; R modified mastectomy; adj. Anastrozole; bone, liver, lymph mets
Treatment post sample grafting: Palliative Gemcitabine and Carboplatin; Palliative Erublin; brain met; whole brain radiation
Pathology specimen type: Bx of sternal lesion
Pathology stage: Not given
Stage at sample grafting: 4
Pathology: Ductal, invasive
Patient tumor grade: 1
Age at diagnosis: 54 (post-menopausal)
Family history: Unknown
Overall survival (months): 36
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 58
Notes:
WHIM59 Metastasis/Recurrence:
Unknown
ER+ (initial) - / PR+ (initial) - / HER2+ (initial) - ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Partial mastectomy and sentinal LN bx; Adj. Taxotere and Cyclophosphamidex4; Arimidex; R breast radiation; skin punch bx TNBC, met to LN, lung, GI and bones
Treatment post sample grafting: Adriamycin, Cytoxanx2, discontinued due to side effects; Xgeva, Pacliataxel; Eribulin; Doxorubicin (liposomal), B chest wall radiation; New bone mets, increased aux. LN mets; CMF; end tx
Pathology specimen type: Unknown
Pathology stage: T1cN0 (at diagnosis)
Stage at sample grafting: 4
Pathology: Ductal, invasive
Patient tumor grade: 3
Age at diagnosis: 58
Family history: Unknown
Overall survival (months): 99
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 59
Notes:
WHIM62 Metastasis: Inguinal LN ER+ / PR+ / HER2- ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: No
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: R. modified radical mastectomy; Adjuvant ACx4; R chest wall and node radiation; Arimidex; bone met; CyberKnife surgery and Aromasin; widespred bone and LN mets; palliative radiation to hip and ribs; Xgeva
Treatment post sample grafting: Fulvestrant, Xegeva; addition of Affinitor; Aromasin added
Pathology specimen type: LN Biobsy
Pathology stage: pT1cN1M0 (at diagnosis)
Stage at sample grafting: 4
Pathology: Ductal, invasive
Patient tumor grade: 3
Age at diagnosis: Unknown (post-menopausal)
Family history: Unknown
Overall survival (months): Still alive at reporting (106)
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 62
Notes: Patient BRACA2+
WHIM63
in stock
Primary: Left Breast ER+ / PR- / HER2- ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: N/A (treatment naïve)
Treatment post sample grafting: Neo adj. AC (x4, skin rash); Epirubicin, Cytoxan; DD taxol; Mastectomy; Goserelin and Exemestane (discontinued due to PD); Metastasis to liver and bone; Sample grafted for WHIM 70; Xeloda, Ruxolitinib/placebo, Boniva on trial; Consent for neratinib Her2 mutation trial; tx switched to Eribulin due to PD; tx switched to Carboplatin and Gemcitabine due to PD
Pathology specimen type: Left breast biopsy during port placement
Pathology stage: cT2N0Mx
Stage at sample grafting: cT2N0Mx
Pathology: Ductal, invasive
Patient tumor grade: 3
Age at diagnosis: 33
Family history: Unknown
Overall survival (months): 15
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 63
Notes: Same Patient as WHIM70
WHIM64 Recurrence: L Chest
wall, skin
ER+ / PR- / HER2- ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Neo-adj. TAC, minimal response; Arimidex; reccurence and LN met; Radiation, low dose Xeloda, hyperthermia; spinal lesions; Tamoxifen; progression in soft tissue and bone; Xeloda, mammoglobin vaccine on study; Affinitor, Aromasin, continued on mammaglobin trial; 4 new spinal lesions; Affinitor, Aromasin on study; Affinitor dose lowered due to mouth sores and weight loss; nodules in chest wall
Treatment post sample grafting: Unknown
Pathology specimen type: Left chest wall skin punch biopsy
Pathology stage: 3B, T2N3a
Stage at sample grafting: 4
Pathology: Lobular Invasive
Patient tumor grade: Not given
Age at diagnosis: Unknown (premenopausal)
Family history: Unknown
Overall survival (months): Unknown
Patient race: Unknown
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 64
Notes:
WHIM65 Residual Primary: Breast ER- / PR- / HER2-
TNBC
ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Neo adj. Carboplatin+Docetaxelx6; R lumpectomy
Treatment post sample grafting: Dose-dense Adriamycin and Cyclophosphamidex4; radiation; unknown
Pathology specimen type: Definitve surgery
Pathology stage: Not given
Stage at sample grafting: Not specified 1/3 LN+
Pathology: Ductal, invasive
Patient tumor grade: 3
Age at diagnosis: 48 (pre-menopausal)
Family history: Unknown
Overall survival (months): Still alive at reporting (19)
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 65
Notes: Patient BRACA1,2 negative
WHIM66 Metastatic/Recurrent:
Chest Wall
ER- / PR- / HER2-
TNBC
ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: No
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Neo adj. Tacol; Neo adj. FAC; L partial mastectomy w L aux. node dissection; Bilateral mastectomy; adj. radiation; chest wall and L internal mamary node reccurence; excisional biopsies; Carboplatin
Treatment post sample grafting: Recurrence in L chest wall and R axcilla; CDX-11 on trial; lung nodule (CDX-11 continued); Eribulin; unknown
Pathology specimen type: Skin punch Biopsy
Pathology stage: cT2N1mx (at diagnosis)
Stage at sample grafting: 4
Pathology: Ductal, invasive
Patient tumor grade: 3
Age at diagnosis: 48 (pre-menopausal)
Family history: Unknown
Overall survival (months): Still alive at reporting (26)
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 66
Notes:
WHIM68 Primary: Breast ER- / PR- / HER2-
TNBC
ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: N/A
Treatment post sample grafting: Neo. Adj. Docetaxel, Carboplatinx6; C1D3 bx; L simple mastectomy w/ axillary LN dissection w/ axillary sentinel LN bx and R prophylctic mastectomy and B breast reconstruction; 1/3 pos sentinel LN; radiation to L chest wall and regional LNs; lung mets; liver mets; Eribulin+Pembrolzumab on trial; R leg DVT; BID Lovenox
Pathology specimen type: Breast biopsy during port placement
Pathology stage: Unknown
Stage at sample grafting: 4
Pathology: Ductal, invasive
Patient tumor grade: 3
Age at diagnosis: 56 (pre-menopausal)
Family history: Unknown
Overall survival (months): Unknown
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 68
Notes: Patient BRCA1/2 negative Same patient as WHIMs 69, 74, 75
WHIM69 Primary: Breast (C1D3) ER- / PR- / HER2-
TNBC
ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Neo. Adj. Docetaxel, Carboplatinx6; C1D3 bx
Treatment post sample grafting: L simple mastectomy w/ axillary LN dissection w/ axillary sentinel LN bx and R prophylctic mastectomy and B breast reconstruction; 1/3 pos sentinel LN; radiation to L chest wall and regional LNs;
lung mets; liver mets; Eribulin+Pembrolzumab on trial; R leg DVT; BID Lovenox
Pathology specimen type: C1D3 core breast biopsy
Pathology stage: Unknown
Stage at sample grafting: 4
Pathology: Ductal, invasive
Patient tumor grade: 3
Age at diagnosis: 56 (pre-menopausal)
Family history: Unknown
Overall survival (months): Unknown
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 69
Notes: Patient BRCA1/2 negative Same patient as WHIMs 68, 74, 75
WHIM70 Metastasis: Liver ER+ / PR- / HER2- ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Sample grafted for WHIM 63; Neo adj. AC (x4, skin rash); Epirubicin, Cytoxan; DD taxol; Mastectomy;
Goserelin and Exemestane (discontinued due to PD); Metastasis to liver and bone;
Treatment post sample grafting: Xeloda, Ruxolitinib/placebo, Boniva on trial; Consent for neratinib Her2 mutation trial; tx switched to Eribulin due
to PD; tx switched to Carboplatin and Gemcitabine due to PD
Pathology specimen type: Liver Biopsy
Pathology stage: cT2N0Mx
Stage at sample grafting: 4
Pathology: Ductal, invasive
Patient tumor grade: 3
Age at diagnosis: 33
Family history: Unknown
Overall survival (months): 15
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 70
Notes: Same Patient as WHIM63
WHIM71 Primary: Breast ER- / PR- / HER2-
TNBC
ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: No
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: N/A
Treatment post sample grafting: Neoadj. Docetaxel, Carboplatin; R lumpectomy w/ sentinel LN biopsy; Adj. radiation to R whole breast x2
Pathology specimen type: Tissue collection during port placement
Pathology stage: Not given
Stage at sample grafting: 2
Pathology: Ductal, invasive
Patient tumor grade: 3
Age at diagnosis: 57 (pre-menopausal)
Family history: Unknown
Overall survival (months): Still alive at reporting (20)
Patient race: African American
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 71
Notes:
WHIM72
in stock
Primary: Right Breast ER+ / PR- / HER2- ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: N/A (treatment naïve)
Treatment post sample grafting: Neo adj. chemo FEC x4; Bilateral Mastectomy w/ auxiliary LN dissection, 10/38 nodes; Taxol switched to Taxotere for cycle 2 due to joint pain; Chest wall radiation; Hormonal Therapy w/ Exemestane plus Triptorelin; Bilateral oophorectomy; Bone met L5; Radiation therapy to L2-L5 plus R hip; Fulvestrant, Palbociclib (42 days stopped due to PD); Erubilin (25% dose reduction to toxicities, stopped due to PD); Enrollment on BIBF-1120 multi-targeted kinase inhibitor trial; Liver met
Pathology specimen type: R core biopsy during port placement
Pathology stage: Unknown
Stage at sample grafting: Unknown
Pathology: Ductal, invasive
Patient tumor grade: 3
Age at diagnosis: 31
Family history: Unknown
Overall survival (months): 26
Patient race: Unknown
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 72
Notes:
WHIM73 Recurrence/Met: Chest wall ER+ / PR- / HER2- ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Yes
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Right mastectomy and LN dissection; ACx4, Tx3; Tamoxifen; Aromasin; recurrence with metastasis soft-tissue mass in anterior R chest wall, adenopathy
Treatment post sample grafting: Weekly taxol; Carboplatin AUC of 2, changed to 1.5 every 2 weeks; taxol discontinued due to neuropathy; Carboplatin discontinued Letrozole and Palbociclib ongoing at reporting
Pathology specimen type: Chest wall biopsy
Pathology stage: T2N1M0 (at diagnosis)
Stage at sample grafting: 4
Pathology: Not given
Patient tumor grade: Not given
Age at diagnosis: Unknown (post-menopausal)
Family history: Unknown
Overall survival (months): Still alive at reporting (>192 )
Patient race: African American
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 73
Notes:
WHIM74 Unknown ER- / PR- / HER2-
TNBC
ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: No
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Neo. Adj. Docetaxel, Carboplatinx6; C1D3 bx
Treatment post sample grafting: L simple mastectomy w/ axillary LN dissection w/ axillary sentinel LN bx and R prophylctic mastectomy and B breast reconstruction; 1/3 pos sentinel LN; radiation to L chest wall and regional LNs;
lung mets; liver mets; Eribulin+Pembrolzumab on trial; R leg DVT; BID Lovenox
Pathology specimen type: Unclear, LN dissection or mastectomy
Pathology stage: Unknown
Stage at sample grafting: 4
Pathology: Ductal, invasive
Patient tumor grade: 3
Age at diagnosis: 56 (pre-menopausal)
Family history: Unknown
Overall survival (months): Unknown
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 74
Notes: Patient BRCA1/2 negative Same patient as WHIMs 68, 69, 75
WHIM75 Metastasis: Liver ER- / PR- / HER2-
TNBC
ESR1 genotype: Unknown
PIK3CA genotype2: Unknown
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: No
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: L simple mastectomy w/ axillary LN dissection w/ axillary sentinel LN bx and R prophylctic mastectomy and B breast reconstruction; 1/3 pos sentinel LN; radiation to L chest wall and regional LNs;
lung mets; liver mets;
Treatment post sample grafting: Eribulin+Pembrolzumab on trial;
R leg DVT; BID Lovenox
Pathology specimen type: Liver biopsy
Pathology stage: Unknown
Stage at sample grafting: 4
Pathology: Ductal, invasive
Patient tumor grade: 3
Age at diagnosis: 56 (pre-menopausal)
Family history: Unknown
Overall survival (months): Unknown
Patient race: Caucasian
Propagated in NSG @ Inotiv: No
Completed efficacy study: No
Estradiol response: Unknown
WHIM number: 75
Notes: Patient BRCA1/2 negative Same patient as WHIMs 68, 69, 74
WHIM81
Available at Washington University in St. Louis
Metastasis: Liver ER+ / PR- / HER2- ESR1 genotype: Unknown
PIK3CA genotype2: Under investigation
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: No
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Unknown
Treatment prior to sample grafting: Neo-adj. Arimidex; Adj. Chemo FEC-Tx3 cycles; Arimidex; recurance in bone; Radiation; BKM120/placebo eith Fulvestrant on study; Xeloda interrupted by radiation to left proximal femur; Palbociclib; Regorafenib, Rafemetinib; Erlubin; Carboplatin, Gemcitabine (\
Carboplatin switched to cisplatin); Palbociclib, Letrozole; Liver met
Treatment post sample grafting: Brain met; Whole brain radiation
Pathology specimen type: Liver Biopsy
Pathology stage: T3N1M0
Stage at sample grafting: 4
Pathology: Ductal
Patient tumor grade: Not given
Age at diagnosis: Unknown (post-menopausal)
Family history: Unknown
Overall survival (months): 110
Patient race: Caucasian
Propagated in NSG @ Inotiv: Yes
Completed efficacy study: Yes
Estradiol response: Unknown
WHIM number: 81
Notes: Patient biopsy was PR+ but PDX tumor is PR-
WHIM84
in stock
Metastasis: Bone L1 ER+ / PR+ / HER2- ESR1 genotype: Unknown
PIK3CA genotype2: Under investigation
p53 genotype: Unknown
Whole genome sequenced: No
Exome sequenced: No
RNAseq: No
Gene expression (microarray data) available: Unknown
Highest ranked phosphoprotein: Unknown
PAM50 subtype originating tumor: Unknown
PAM50 subtype early passage PDX: Unknown
PAM50 subtype late passage PDX: Neo. Adj. MK-2206 on trial, continued on Arimidex alone; sentinel; node positive for metastasis; Adj. TCx4; Radiation; Anastrozole; Bone met (L1)
Treatment prior to sample grafting: Radiation to spine and left femur; CMF, discontinued due to progression; Fulvestrant with addition of Palbociclib; Brain met; Cepecitabine; Unknown
Treatment post sample grafting: Bone L1 Biopsy
Pathology specimen type: cT2N0
Pathology stage: 4
Stage at sample grafting: Ductal; Invasive
Pathology: Not given
Patient tumor grade: Unknown (post-menopausal)
Age at diagnosis: Unknown
Family history: Alive at reporting (57 months)
Overall survival (months): Caucasian
Patient race: In Progress
Propagated in NSG @ Inotiv: Yes
Completed efficacy study: In progress
Estradiol response: Unknown
WHIM number: 84
Notes: Patient biopsy was PR- but PDX tumor is PR+

Subscribe to updates from Inotiv

Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.

Subscribe now